Patent DE1011539B successfully refreshed from Google Patents.
EP0289336A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Aerosolization of protein therapeutic agent
Assignee: Cooper Laboratories Inc
•
Filing: 1988-04-29
•
Granted: —
•
Expires: 2008-04-29
Abstract
Abstract Aerosolization of therapeutic proteins is demonstrated using recombinant α₁-antitrypsin for treatment of emphysema as paradigmatic.
Inventors
- 👤 Nicolaas J. Roosdorp
- 👤 Ronald G. Crystal
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 14:46
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/007; A61K9/0073; A61K9/0078; A61K38/00; A61K38/16; A61K38/55; A61K38/57
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
22 words
An aerosol formulation comprising from about 0.1 to 15% of a peptide agent used for prophylactic or therapeutic treatment of the lungs.
Claim 2
Dependent Claim
22 words
An aerosol formulation comprising from about 0.1 to 15% of a peptide agent used for prophylactic or therapeutic treatment of the lungs.
Claim 3
Dependent Claim
21 words
An aerosol formulation according to claim 1, wherein said peptide agent is present in from about 0.5 to 10 weight percent.
Claim 4
Dependent Claim
17 words
An aerosol formulation according to any of claims 1 or 2, wherein said peptide agent is α₁-trypsin.
Claim 5
Dependent Claim
20 words
An aerosol formulation according to any one of the preceding claims, wherein said peptide is of at least 30 kD.
Claim 6
Dependent Claim
20 words
An aerosol formulation according to any one of the preceding claims, wherein said peptide agent is produced by recombinant techniques.
Claim 7
Dependent Claim
15 words
An aerosol formulation according to claim 5, wherein said peptide agent is produced in yeast.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.